home / stock / kttaw / kttaw news

KTTAW News and Press, Pasithea Therapeutics Corp. Warrant From 12/11/23

Stock Information
Company Name: Pasithea Therapeutics Corp. Warrant
Stock Symbol: KTTAW
Market: NASDAQ
Website: pasithea.com
Menu
KTTAW KTTAW Quote KTTAW Short KTTAW News KTTAW Articles KTTAW Message Board
Get KTTAW Alerts

News, Short Squeeze, Breakout and More Instantly...
KTTAW - Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

-- Preclinical data continues to demonstrate PAS-004’s potentially superior properties as compared to FDA approved MEK inhibitors -- -- Once daily dose of PAS-004 delivers anti-tumor efficacy in in vivo NRAS mutation cancer models -- SOUTH SAN FRANCISCO, Calif. and ...
KTTAW - Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

SOUTH SAN FRANCISCO, Calif. and MIAMI, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (NASDAQ: KTTA), today announced that its annual meeting of stockholders held on November 29, 2023 (the “Annual Meeting”) was...

KTTAW - Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

-- Company on track to submit PAS-004 IND application in current quarter -- -- Pasithea plans to begin PAS-004 Phase 1 dose escalation trial in advanced solid tumor patients harboring RAS, RAF and NF1 mutations -- SOUTH SAN FRANCISCO, Calif. and MIAMI, Nov. 29, 2023 (GLOBE NEWSW...

KTTAW - Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets ?5?1 Integrin for the Treatment of both Sporadic and Familial ALS

-- Blocking of α5β1 integrin has been shown to improve motor function and increase survival in the SOD1 G93A mouse model of ALS -- -- Fully humanized anti-α5β1 monoclonal antibody is ready for manufacture and IND-enabling studies -- SOUTH SAN FRANCI...
KTTAW - Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

PALO ALTO, Calif. and MIAMI, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CN...

KTTAW - Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

-- Attendees may request 1 x 1 meeting with management at meetings@hcwco.com -- PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), ...

KTTAW - Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in ?5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting ?5 integrin results in improved surviv

-- PAS-003 is a monoclonal antibody targeting α 5/ β1 integrin for the treatment of amyotrophic lateral sclerosis (“ALS”) -- -- Lead α 5/ β1 integrin drug candidate to be se...
KTTAW - Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

PALO ALTO, Calif. and MIAMI, July 20, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system ...

KTTAW - Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.

PALO ALTO, Calif. and MIAMI, July 20, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous sys...

KTTAW - Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors

PALO ALTO, Calif. and MIAMI, June 30, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous sys...
Previous 10 Next 10